Importantly, BET inhibition has been shown to antagonize the disease phenotype in MPN mouse models and to augment disease inhibition by ruxolitinib, including impressive effects on allele burden and reversal of bone marrow fibrosis, in part by inhibiting the transcriptional activation of NFκB target genes [110]. Here, NFKB1 is linked to myeloproliferative disorder.